{"id":"sii-licensed-ipv","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"}]},"_chembl":{"chemblId":"CHEMBL55632","moleculeType":"Small molecule","molecularWeight":"563.70"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine contains a weakened form of the poliovirus, which triggers an immune response and helps the body develop immunity against future infections. This immune response is specific to the poliovirus and does not provide protection against other types of viruses.","oneSentence":"IPV vaccine works by stimulating the body's immune system to produce antibodies against the poliovirus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:30.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis"}]},"trialDetails":[{"nctId":"NCT05163561","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2022-01-09","conditions":"Poliomyelitis","enrollment":1072},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Sii Licensed IPV","genericName":"Sii Licensed IPV","companyName":"Serum Institute of India Pvt. Ltd.","companyId":"serum-institute-of-india-pvt-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"The SII Licensed IPV is an inactivated poliovirus vaccine used to study poliomyelitis, as per a Phase III clinical trial (NCT05163561) conducted by the Serum Institute of India Pvt. Ltd. The vaccine is classified as a small molecule modality, according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}